Skip to main content

Stay Updated on Stockhausen – News and Insights

Clover Announces Positive Phase 2 Clinical Data for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates in Older Adults

— Positive Phase 2 (Australia) results strengthen potential best-in-class profile of RSV+hMPV±PIV3 combination vaccines, with the potential differentiated ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore and broaden protection —- Robust neutralizing antibody responses across…

Women Leaders Association Adds Lisa Reilly as Boston Coaching Partner, Bringing 23 Years of Biotech Leadership and Her Reclamation Method to High-Achieving Women

The association’s Boston Coaching Partners roster grows to three — adding an executive and career coach who helps high-performing women lead with clarity, confidence, and authenticity without sacrificing themselves in the processBOSTON, Aug. 29, 2026 /PRNewswire/ — The…

AusperBio Completes $120 Million Series C Financing to Advance AHB-137 Toward Potential Commercialization and Expand Next-Generation HBV Therapies

Financing supports advancement of AHB-137 toward potential commercialization, including its Phase 3 registrational program and commercialization readinessProceeds will also accelerate AHB-171 and next-generation combination approaches designed to advance functional cure for chronic hepatitis BSeries C brings AusperBio’s total…

Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion

TAIPEI, Aug. 23, 2026 /PRNewswire/ — Anbogen Therapeutics Inc. (TPEx: 7784) (“Anbogen” or the “Company”), a clinical-stage precision oncology company, today announced that it has entered into a Collaborative Research Agreement (CRA) with the Laboratory of Veterinary Surgery, Graduate…